Breast density changes associated with hormone replacement therapy in postmenopausal women. Effects on the specificity and sensitivity of mammographic screening

Postmenopausal HRT use is associated with an increase of mammographic density and reduction of sensitivity and specificity of mammography results and an increase of false-positive and false-negative outcomes. The increased density does not allow a good evaluation of the exam. Mammographic density is an independent risk factor for breast cancer, but the link between changes in breast density and difference in breast cancer risk, remain uncertain. On the other hand, today specific guidelines and protocols to optimize the screening of neoplastic breast pathology in HRT users do not exist and it is unknown if short-term suspension of therapy improves mammographic sensitivity. More information is required to define this important risk factor.

HRT; Mammographic density; Breast cancer detection

[1] ACOG committee opinion. Routine Cancer Screening. Number 247, December 2000. Int. J. Gynaecol. Obstet., 2003, 82, 241.

[2] Greendale G.A., Reboussin B.A., Sie A., Singh H.R., Olson L.K., Gatewood 0. et al.: "For the Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Effects of estrogen and estrogen-progestin on mammographic parenchymal density". Ann. Intern. Med., 1999, 130, 262.

[3] Greendale G.A., Reboussin B.A., Slone S., Wasilauskas C., Pike M.C., Ursin G.: "Postmenopausal hormone therapy and change m mammographic density". J. Natl. Cancer Inst., 2003, 95, 30.

[4] McNagny S.E.: "Prescribing hormone replacement therapy for menopausal symptoms". Ann. Intern. Med., 1999, 131, 605.

[5] Sala E., Warren R., McCann J., Duffy S., Luben R., Day N.: "High-risk mammographic parenchimal patterns, hormone replacement therapy and other risk factors: a case control study". Int. J. Epid., 2000, 29, 629.

[6] Ga yet A., Esteve J., Seradour B., Piana, L. Jacquemier J.: "Does hormone replacement therapy increase the frequency of breast atypical hyperplasia in postmenopausal women? Results from the Bouches du Rhone district screening campaign". Eur. J. Cancer, 2003, 39, 1738.

[7] Colacurci N., Mele D., De Feanciscis P., Costa V., Fortunato N., De Seta L.: "Effects of tibolone on the breast". Eur. J. Obstet. Gynecol. Reprod. Biol., 1998, 80, 235.

[8] Eral C.T., Elter K., Akaman C., Ersavasti G., Altug A., Seyisoglu H., Ertungealp E.: "Mammographic changes in women receiving tibolone therapy". Fertil. Steril., 1998, 69, 870-87546 - American Cancer Society Guidelines for Breast Cancer Screening: Update 2003. CA Cancer J. Clin., 2003, 54, 141.

[9] Lundstrom E., Wilczek B., von Palffy Z., Soderqvist G., von Schoultz B.: "Mammographic breast density during hormone replacement therapy: Differences according to treatment". Arn. J. Obstet. Gynecol., 1999, 181, 348.

[10] Potten C.S., Watson R.J., Williams G.T., Tickle S., Roberts S.A., Harris M. et al.: "The effect of age and menstrual cycle upon proliferative activity of the normal buman breast". Br. J. Cancer, 1988, 58, 163.

[11] Anderson T.J.: "Mitotic activity in the breast". J. Obstet. Gynaecol., 1984, 4, S114.

[12] Malberger E., Gutterman E., Bartefeld E., Zajicek G.: "Cellular changes in the mammary gland epithelium during the menstrual cycle. A computer image analysis study". Acta Cytol., 1987, 31, 305.

[13] Olsson H., Jernstrom H., Alm P., Kreipe H., Ingvar C., Jonsson P.E. et al.: "Proliferation of the breast epithelium in relation to meustrual cycle phase, hormone use, and reproductuve factors". Breast Cancer Res. Treat., 1996, 40, 187.

[14] Soderqvist G.,Isaksson E., van Schoultz B., Carlstrom K., Tani E., Skoog L.: "Proliferation of breast epithelial cells in healthy women dunng the mcustruaJ cycle". Arn. J. Obstet. Gynecol., 1997, 176, 123.

[15] Gompel A., Martin A., Simon P., Schoevaert D., Pilu-Bureau G., Hugol D. et al.: "Epidermal growth factor receptor and c-erb-2 expression in normal breast tissue during menstrual cycle". Breast Cancer Res. Treat., 1996, 38, 227.

[16] Dabrosin C., Hallstrom A., Ungerstedt U., Hammar M.: "Microdialysis of human breast tissue during the menstrual cycle". Clin. Sci. (Co/ch), 1997, 92, 493.

[17] Baines CJ., Dayan R.A., Tangled Web: "Factors likely to affect the efficacy of screening mammography". J. Natl. Cancer Inst., 1999, 91, 833.

[18] Colacurci N., Fomaro F., De Franciscis P., Mele D., Palermo M., de! Vecchio W.: "Effect of a short-term suspension of hormone replacement therapy on mammographic density". Fertil. Steril., 2001, 76, 451.

[19] Anastassiades O.T., Spiliades C., Tsakraklides E., Gogas J.: "Amount and distribution of solid and fatty tissues in the female breast and their ralationship to carcinoma". Pathol. Res. Pract., 1983, 176, 200.

[20] Brisson J., Morrison A.S., Khalid N.: "Mammographic parenchymal features and breast cancer in the Breast Cancer Detection Demonstration Project (published erratum appears in.!. Natl. Cancer Inst. 1989, 81, 1513)". J Natl. Cancer Inst., 1988, 80, 1534.

[21] Spicer D.V., Ursin G., Parisky Y.R., Pearce J.G., Shoupe D.,Pike A. et al.: "Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk". J. Natl Cancer Inst., 1994, 86, 431.

[22] Chlebowski R.T., McTiernan A.: "Biological significance of interventions that change breast density". J. Natl Cancer Inst., 2003, 95, 4.

[23] Evans A.: "Hormone replacement therapy and mammographic screening". Clin. Rad., 2002, 57, 563.

[24] Haiman C.A., Hankinson S.E., De Vivo I., Guillemette C., lshibe N., Hunter D.J., Byme C.: "Polymorphisms in steroid hormone pathway genes and mammographic density". Breast Cancer Res. Treat., 2003, 77, 27.

[25] Kolb T.M., Lichy J., Newhouse J.H.: "Comparison of the performance of screening mammography, physicaJ examination, and breast US and evaluation of factors that inf1uence them: an analysis of 27,825 patient evaJuations". Radiology, 2002, 225, 165.

[26] Bulbul N.H., Ozden S., Dayicioglu V.: "Effects of hormone replacement therapy on marnmographic findings". Arch. Gynecol. Obstet., 2003, 268, 5-8. Epub 2002 June 06.

[27] Carney P.A., Miglioretti D.L., Yankaskas B.C., Kerlikowske K., Rosenberg R., Rutter C.M. et al.: "Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography". Ann. Intern. Med., 2003, 138, 168.

[28] Carney P.A., Miglioretti D.L., Yankaskas B.C., Kerlikowske K., Rosenberg R., Rutter C.M. et al.: "Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography". Ann. Intern. Med., 2003, 138, 168.

[29] Dixon J.M.: "Hormone replacement therapy and the breast". Br. Med. J., 2001, 323, 1381.

[30] Kavanagh A.M., Mitchell H., Giles G.G.: "Hormone replacement therapy and accuracy of mammographic screening". Lancet, 2000, 355, 270.

[31] Lundstrom E., Christow A., Kersemaekers W., Svane G., Azavedo E., Stiderqvist G. et al.: "Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density". Arn. J. Obstet. Gynecol., 2002, 186, 717.

[32] Ozdemir A., Konus 0., Nas T., Erbas G., Cos S., Is S.: "Mammographic and ultrasonographic study of changes in the breast related to HRT" Int. J. Gynaecol. Obstet., 1999, 67, 23.

[33] Rutter C.M., Mandelson M.T., Laya M.B., Seger DJ., Taplin S.: "Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy". JAMA, 2001, 285, 171.

[34] Slanetz P.J.: "Hormone replacement therapy and breast tissue density on mammography". Menopause, 2002, 9, 82.

[35] Laya M.B., Larson E.B., Taplin S.H., White E.: "Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography". J. Nat. Cancer Inst., 1996, 88, 643.

[36] Million Women Study Collaborators: "Breast cancer and hormone-replacement therapy in the Million Women Study". Lancet, 2003, 362, 419.

[37] U.S. Preventive Services Task Force: "Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: recommendations and rationale". Ann. Intern. Med., 2002, 137, 834.

[38] Egan R.L., Mosteller R.C.: "Breast cancer mammography patterns". Cancer, 1972, 40, 2087

[39] Nystrom L., Andersson I., Bjurstam N., Frisell J., Nordenskjiild B., Rutqvist L.E.: "Long-term effects of mammography screening: updated overview of the Swedish randomised trials". Lancet, 2002, 359, 909.

[40] Speroff L.: "The meaning of mammographic breast density in users of postmenopausal hormone therapy". Maturitas, 2002, 4I, 171.

[41] Vachon CM, Se\lers TA, Vierkant RA, Fang-Fang Wu, Brandt KR. Case-Control Study of Increased Mammographic Breast Density Response to Hormone Replacement Therapy. Cancer Epidemiol Biomarkers Prev., 2002, 11, 1382.

[42] Sendag F., Cosan Terek M., Ozsener S., Oztekin K.,Bilgin O.,Bilgen I., Memis A.: "Mammographic density changes during different postmenopausal hormone replacement therapies". Fertil. Steril., 2001, 76, 445.

[43] Harvey J.A., Pinkerton J.V., Herman C.R.: "Short-term cessation of hormone replacement therapy and improvement of mammographic specificity". J. Natl Cancer Inst., 1997, 89, 1623.

[44] Wolfe J.N.: "Breast patterns as an index of risk for developing breast cancer". Lancet, 1997, 350, 1047.

[45] Banks E., Reeves G., Bera! V., Bull D., Crossley B., Simmonds M., Hilton E., Bailey S., Barret N., Briers P., English R., Jackson A., Kutt E., Lavelle J., Rockall L., Wallis M.G., Wilson M., Patnick J. : "Impact of use of hormone replacement therapy on false positive recall in the NHS breast screening programme: results from the million women study". Br. Med. J., 2004, 328, 1291.